8-K

================================================================================



                     U.S. SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported): July 16, 2007

                              ONCOLOGIX TECH, INC.
            ---------------------------------------------------------
           (Name of Small Business Issuer as Specified in Its Charter)

                                    0-15482
                             ----------------------
                            (Commission File Number)

             Nevada                                              86-1006416
 ------------------------------                               -----------------
(State or other jurisdiction of                              (I.R.S. Employer
 incorporation or organization)                              Identification No.)

                    3725 Lawrenceville-Suwanee Rd., Suite B-7
                                Suwanee, GA 30024
                     --------------------------------------
                    (Address of principal executive offices)

                                 (770) 831-8818
                            -------------------------
                           (Issuer's telephone number)

Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:

[  ] Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
     CFR 240.14a-12)

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))



================================================================================




Item 8.01     Other Events.

         On July 16, 2007, we discovered, during additional testing of our
Oncosphere product, more rigorous than our original feasibility testing, a rate
of radiation leaching from the microsphere surface higher than anticipated.
"Leaching" refers to the amount of radiation physically released from the
microspheres that had been previously thought to be bound. We believe that the
level of leaching observed is high enough that future progress with the product
requires further investigation into process and material modifications to reduce
or eliminate the leaching. We believe that in accomplishing this, we will need
to replace one or more of the constituent components of the Oncosphere with
similar or new components. We have already begun to explore and test several
alternative processes and materials that we believe would meet the performance
conditions expected in the human body and the requirements of the FDA. Testing
that simulates the conditions of the body is required by medical device
standards and the FDA.

         Subject to further review, we believe that there is sufficient cash on
hand to enable us to develop and test a new design within approximately two
months. There is no assurance that the necessary re-design can be accomplished
with those funds and within that time or even at all. Our previous estimate that
approximately $5,000,000 will be required to complete the pre-clinical testing
phase and the clinical approval phase, has been revised to a requirement of
approximately $6,000,000.

         Our ability to complete any new development is dependent on our
ability, which is uncertain, to raise additional funds from the proceeds of new
loans or the sale of additional equity. As with any development stage medical
device product, there can be no guarantee that even with sufficient funds the
product design will be successful or that the FDA will ultimately provide
approval for its clinical or commercial use.

Item 9.01     Financial Statements and Exhibits.

(d)  Exhibits.

Exhibit        Title

99             Press release issued by Oncologix Tech, Inc., dated July 19,
               2007.




                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.


Dated: July 19, 2007                        ONCOLOGIX TECH INC.


                                            By:  /s/  Andrew M. Green
                                               --------------------------------
                                                      Andrew M. Green,
                                                      Chief Executive Officer
                                                      and President

                                            By:  /s/  Michael A. Kramarz
                                               --------------------------------
                                                      Michael A. Kramarz,
                                                      Chief Financial Officer

EX-99

                                                                      EXHIBIT 99

         ONCOLOGIX TECH ANNOUNCES THAT ADDITIONAL DESIGN AND TESTING OF
          THE ONCOSPHERE SYSTEM IS REQUIRED FOR CLINICAL ACCEPTABILITY

SUWANEE, Georgia.--(Market wire) July 19, 2007 - Oncologix Tech Inc. (OTC BB:
OCLG.OB) announced today that recent testing of its Oncosphere product, more
rigorous than the original feasibility testing, has revealed a rate of radiation
leaching from the microsphere surface higher than anticipated. "Leaching" refers
to the amount of radiation physically released from the microspheres that had
been previously thought to be bound. Oncologix believes that the level of
leaching observed is high enough that future progress with the product requires
further investigation into process and material modifications to reduce or
eliminate the leaching. Oncologix further believes that in accomplishing this,
it will need to replace one or more of the constituent components of the
Oncosphere with similar or new components. Exploration and testing have already
begun on several alternative processes and materials that it is believed would
meet the performance conditions expected in the human body and the requirements
of the FDA. Testing that simulates the conditions of the body is required by
medical device standards and the FDA.

Subject to further review, the announcement stated the Company's belief that
there is sufficient cash on hand to enable it to develop and test a new design
within approximately two months. There is no assurance that the necessary
re-design can be accomplished with those funds and within that time or even at
all. The previous estimate that approximately $5,000,000 will be required to
complete the pre-clinical testing phase and the clinical approval phase, has
been revised to a requirement of approximately $6,000,000.

Our ability to complete any new development is dependent on our ability, which
is uncertain, to raise additional funds from the proceeds of new loans or the
sale of additional equity. As with any development stage medical device product,
there can be no guarantee that even with sufficient funds the product design
will be successful or that the FDA will ultimately provide approval for its
clinical or commercial use.

Andrew Green, President and CEO of Oncologix stated, "Our objective will be to
continue to design, test, and provide medical products that meet the highest
standards for safety and effectiveness. We are optimistic about our new approach
and believe that if successful, we will have a product that has expanded
possibilities for diagnostic and therapeutic applications."

About Oncologix Tech Inc. and its subsidiary, Oncologix Corporation:
- --------------------------------------------------------------------
Oncologix Tech Inc. (formerly BestNet Communications Corp.) was previously a
provider of long distance telephone communication services but disposed of that
business in January 2007.

The Company is developing a brachytherapy (radiation therapy) device, the
Oncosphere System, for the advanced medical treatment of soft tissue cancers. It
is based on radioactive microparticles designed to deliver therapeutic radiation
directly to a tumor site by introducing the microparticles into the artery that
feeds the tumor tissue.

This release contains forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended, which are intended to be
covered by the "safe harbor" created thereby. These statements include the plans
and objectives of management for future operations, including plans and




objectives. The forward-looking statements herein are based on current
expectations that involve judgments with respect to, among other things, future
economic, competitive and market conditions and future business decisions, all
of which are difficult or impossible to predict accurately and many of which are
beyond control of the company. Although the company believes that the
assumptions underlying the forward-looking statements are reasonable, any one of
the assumptions could be inaccurate, and therefore it can provide no assurance
that the forward-looking statements included in this release will prove to be
accurate.



                                      # # #